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Abstract 
Background: The treatment of immune suppression dependent minimal change nephropathy (MCN) can be chal-
lenging and frequently leads to serious complications. In paediatric patients, successful treatment with rituximab is 
described in steroid-dependent MCN. There is limited information about the potential efficacy of rituximab for the 
treatment of MCN in adults and adolescence. We describe our experience with rituximab in adolescent and adult 
patients with immune suppression dependent MCN.
Results: Ten adolescents and adults with immune suppression dependent MCN and therapy related complications were 
treated with rituximab. At a mean age of 26 years, about 10.5 years after first presentation, they received two doses of 
rituximab (375 mg/m2). Maintenance immunosuppressive medication was stopped. After a mean follow-up of 43 months, 
three patients had four relapses. Three relapses were successfully retreated with rituximab again, after induction therapy 
with 60 mg prednisone per day. Rituximab was well tolerated and no infectious complications were recorded.
Conclusion: Treatment with rituximab induces a long-term remission of immune suppression dependent MCN in 
adolescents and adults. A timely treatment with rituximab could be considered to limit side effects of immunosup-
pressive medication.
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Background
Minimal change nephropathy (MCN) is the most com-
mon cause of childhood onset nephrotic syndrome [1]. 
MCN usually responds well to prednisone, but up to 70% 
of the patients have one or more relapses of the nephrotic 
syndrome [2, 3]. A considerable part may become ster-
oid-dependent and over half of the patients with MCN 
require additional immunosuppressive therapy [3]. 
Generally the nephrotic syndrome will go into definite 
remission after puberty, but up to 25% of the children 
with MCN will continue to suffer from relapses in adult-
hood [4]. Patients with frequent relapses of the nephrotic 
syndrome are exposed to long periods of prednisone 
and have a high risk of therapy-related complications 
[4]. Other immunosuppressive medication such as cal-
cineurin inhibitors and cyclophosphamide can reduce 
the cumulative dose of steroids. However, these second-
line medications may have serious side effects or limited 
effectiveness. In recent years, successful treatment with 
rituximab was described for MCN in children. After 
treatment with rituximab there are less relapses of the 
nephrotic syndrome and other immunosuppressive ther-
apy could be substantially reduced [5–8]. There is limited 
information about the potential efficacy of rituximab for 
the treatment of MCN in adults and adolescence [9–16]. 
We describe a series of patients with immune suppres-
sion dependent MCN, treated with rituximab in adoles-
cence and adulthood.
Results and discussion
The patients (Additional file  1: Table  S1) with a mean 
age of 26 (14–56) years had the first presentation of the 
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nephrotic syndrome in childhood (4 cases), adolescence 
(4 cases) and adulthood (2 cases). The first presentation 
of the nephrotic syndrome was at an average age of 16 
(3–52) years. The mean duration of the nephrotic syn-
drome was 10.5 (0.5–23) years.
After treatment of rituximab, there was a mean follow-
up of 43  months (16–76  months). In this period, three 
patients had four relapses. One patient (number 9) with 
a relapse after 24  months and another patients (num-
ber 5) with two relapses (21 and 36 months after initial 
rituximab treatment) were successfully retreated with 
rituximab after remission induction therapy with 60 mg 
prednisone/day. Both patients still have a complete 
response 37 and 43  months after last retreatment with 
rituximab respectively.
The fourth patient (number 3) had a relapse after 
21 months, but retreatment with steroids and rituximab 
was unsuccessful. The nephrotic syndrome came into 
remission with prednisone and cyclosporine mainte-
nance therapy.
In all patients, rituximab treatment lead to a total 
depletion of circulating B cells for at least 1 month. After 
1 month, the B cell counts were not routinely measured.
Rituximab was well tolerated, except for one patient 
who had an allergic reaction during the first treatment. 
Although the infusion of rituximab was stopped half-
way the peripheral B-cells were fully depleted and the 
nephrotic syndrome went into complete remission with-
out further need for maintenance immunosuppressive 
medication. None of the patients had infectious compli-
cations after treatment with rituximab. In contrast, all 
patients had experienced serious side effects of the pre-
vious (maintenance) immunosuppressive therapy (Addi-
tional file 1: Table S1).
Discussion
The treatment of immune suppression dependent MCN 
is challenging. Although the nephrotic syndrome usually 
responds well to prednisone [17, 18], long-term use has 
serious complications: obesity, cushingoid habitus, oste-
onecrosis and cataract. Cyclophosphamide, cyclosporine, 
mycophenolate mofetil or levamisole are commonly 
used as second-line treatment [5]. Cyclosporine main-
tenance therapy is usually effective, but relapses often 
occur after discontinuation [19]. Cyclosporine can cause 
renal dysfunction, hypertension and gingival hyperpla-
sia. Mycophenolate mophetil may reduce the frequency 
of relapses [20], but is its use may be limited by gastro-
intestinal side effects. Maintenance therapy with levami-
sole, can reduce the number of relapses, but is not known 
to induce long term remission. In addition, levamisole is 
not available in every country and could induce agranu-
locytosis [5, 21]. Only the use of cyclophosphamide may 
induce a long term remission of MCN in about half of 
the patients, but cytotoxicity and the risk of infertility are 
potential serious side effects [22].
In recent years, a number of publications in paediat-
ric patients have reported that rituximab is an effective 
treatment in steroid-sensitive, but immune suppression 
dependent nephrotic syndrome. In these children, rituxi-
mab treatment seems to be able to reduce the relapse 
rate, although the immunosuppressive medication was 
reduced or even discontinued [5–8, 23–26]. The treat-
ment with rituximab in steroid-resistant nephrotic syn-
drome is considerable less effective [24, 27].
The data about the efficacy of rituximab for MCN in 
adult patients is limited, but seem to confirm the posi-
tive results in children [9–16]. Our data show that ado-
lescents and adults with immune suppression-dependent 
MCN have a remarkable good long term remission in 
response to rituximab treatment. Even more remark-
able, long term remission was achieved in patients with 
immune suppression dependent MCN many years after 
the first presentation and after different immune sup-
pressive drugs and combinations thereof.
Although the pathophysiology of MCN is unknown, 
the immune system and especially the T-cells seem to 
play a role [28]. A circulating factor originating from 
patient’s T-cells can induce MCN in animals [29]. The 
regulatory T-cells of patients with MCN are less effec-
tive compared with T-cells of healthy. When MCN is in 
remission, these regulatory T-cells functionally improve 
[30]. Therefore it is interesting that administration of 
rituximab, a monoclonal antibody directed against CD20, 
expressed on B-cells, is an effective therapy. In recent 
years, it is reported that the B-cell has also regulatory 
functions. The regulatory B-cell stimulates both effec-
tor and regulatory T-cells [31]. In other auto-immune 
diseases the regulatory T-cell function improves after 
treatment with rituximab [32]. The mechanism of action 
is unknown, but maybe B-cell depletion results in a new 
balance between the various T-cell subsets. This balance 
may establish even after repopulation of the peripheral 
B-cell population. A suggested mechanism is that T-cells, 
that interact with B-cells, are removed simultaneous after 
treatment with rituximab [33]. Otherwise it is also possi-
ble that the B-cell has a direct role in the pathogenesis of 
MCN, but evidence for this position is lacking.
Beside an immunological explanation, rituximab may 
have a direct effect in the kidney. A recent study shows 
that rituximab may stabilize the cytoskeleton of the 
podocyte [34].
We treated our patients with 2 doses of rituximab with 
a one- or two-week interval, when nephrotic syndrome 
was in complete remission. Our experience is in agree-
ment with the notion that rituximab seems to be most 
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effective as a remission maintenance drug after induction 
therapy to achieve complete remission of the MCN [5]. 
Published studies vary in their dose and number of doses 
rituximab to achieve long-term remission of MCN. A sin-
gle dose of rituximab achieved a good response in a series 
of 12 patients, described by Kamei et al., but the relapse 
rate was 75% [7]. Another study observation that the time 
to relapse of the nephrotic syndrome was longer when 
initially more than three doses were given [23]. An unan-
swered question is whether rituximab treatment should 
be repeated after repopulation of the peripheral B-cell 
population in order to achieve protracted remission. The 
nephrotic syndrome relapses usually only after repopula-
tion of the peripheral B-cell population [5, 6]. However 
a large part of the patients have a sustained complete 
remission, even after repopulation of peripheral B-cells 
and we therefore did not follow this strategy [6].
Rituximab was well tolerated in our patients. Only one 
patient had an allergic reaction and infusion was stopped. 
In previous studies, about 50% of the patients had some 
complaints when rituximab was administered, but there 
was no need to stop administration. These symptoms 
are usually mild and concerns hypotension, tachycardia, 
dyspnoea and cutaneous rash [5, 6].
Although rituximab causes an average of 6  months 
B-cell depletion, infectious complications are scarce 
[5, 6]. A slight depression of serum immunoglobu-
lins is described [35]. Seldom severe complications are 
pneumocystis jirovecii pneumonia, severe colitis and 
pulmonary fibrosis [5, 36, 37]. Progressive multifocal 
leucoencephalopathy is associated with the use of rituxi-
mab, but this complication is never described in children 
treated with rituximab [35]. Adverse events following 
treatment of rituximab may be dependent of concomitant 
use of immunesuppressive agents and underlying condi-
tions [35]. After treatment with rituximab we recorded 
no infectious complications. These limited side-effects of 
the rituximab treatment are in contrast to complications 
the other immunosuppressive medications.
Conclusion
In conclusion, our series of patients shows a remark-
able efficacy of rituximab for the induction of long-term 
remission of immune suppression dependent MCN in 
adolescents and adults. In the group of patients with 
immune suppression dependent MCN, with frequent 
relapses and therapy related complications, a timely 
treatment with rituximab could be considered to limit 
side effects.
Methods
We describe retrospective our experience with the treat-
ment of rituximab in adolescent and adult patients with 
biopsy proven MCN, who need maintenance immuno-
suppressive therapy for sustained remission. All patients 
had normal renal function. They were treated with rituxi-
mab because of serious complications due to immuno-
suppressive medication, frequent relapses or at patients 
request to stop maintenance immunosuppressive medi-
cation. When the nephrotic syndrome was in remission 
with immunosuppressive therapy, they were treated with 
2 doses of 375 mg/m2 rituximab with a 1 (patients 8–10) 
or 2 (patients 1–7) week interval.
Following treatment with rituximab, the dose of pred-
nisone was tapered rapidly and other immunosuppres-
sive medication was stopped within 1  month after the 
last administration of rituximab.
Consent
Written informed consent for publication of this case 
series was obtained from all ten patients. A copy of the 
written consent is available for review by the Editor-in-
Chief of this journal.
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